Table 2: Description of treatment in patients with inactive and active lupus.
| Medications |
SLEDAI=0
(n=37) |
SLEDAI>0
(n=44) |
p Value* |
| Corticosteroids (%) |
32.4 |
47.8 |
0.183 |
| Immunosuppressive dose (%) |
37.8 |
23.9 |
0.229 |
| Antimalarial (%) |
86.5 |
73.9 |
0.182 |
| Azathioprine (%) |
40.5 |
45.7 |
0.663 |
| Cyclophosphamide (%) |
5.4 |
13.0 |
0.289 |
| Micophenolate (%) |
11.1 |
11.4 |
1.000 |
| Methotrexate (%) |
8.1 |
4.3 |
0.652 |
| Anti-hypertensive drugs (%) |
45.9 |
63.0 |
0.128 |
| Statins (%) |
18.8 |
24.3 |
0.771 |
ANA: Antinuclear Antibody; CRP: C-Reactive Protein; ESR: Erythrocyte Sedimentation Rate; SD: Standard Deviation; SLEDAI: Systemic Lupus Erythematous Disease Activity Index; SLICC: Systemic Lupus International Collaborating Clinics; MPV: Mean Platelet Volume; VDRL: Venereal Disease Research Laboratory Test.
*Chi square test for qualitative